Vertex Pharma Stock: DOWN 6.8% Despite Blockbuster Drugs! Should YOU Buy?
How could a company known for blockbuster drugs like Trikafta bafflingly underperform the market? Vertex Pharmaceuticals, a biopharma leader with an $111 billion market cap, has seen its VRTX stock slip significantly, lagging both the S&P 500 and the broader healthcare sector. Specifically, setbacks in its pain-drug pipeline, including a failed trial and FDA hesitation, have dramatically shaken investor confidence in its diversification efforts beyond cystic fibrosis. Despite these challenges, analysts maintain a "Moderate Buy" rating, anticipating substantial EPS growth for 2025. Intriguingly, this positive sentiment has even grown recently. Make sure to subscribe to our channel for more deep dives into investment opportunities.
Tags/Hashtags: #vrtx #vrtx #xlv #analysts
Leave a Reply